MAYLANDI Trademark

Trademark Overview

On Thursday, November 9, 2023, a trademark application was filed for MAYLANDI with the United States Patent and Trademark Office. The USPTO has given the MAYLANDI trademark a serial number of 98262594. The federal status of this trademark filing is THIRD EXTENSION - GRANTED as of Friday, January 23, 2026. This trademark is owned by Novast Laboratories, Inc.. The MAYLANDI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of menopausal symptoms; hormone replacement therapy preparations
maylandi

General Information

Serial Number98262594
Word MarkMAYLANDI
Filing DateThursday, November 9, 2023
Status732 - THIRD EXTENSION - GRANTED
Status DateFriday, January 23, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 4, 2024

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of menopausal symptoms; hormone replacement therapy preparations

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, December 11, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameNovast Laboratories, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPlano, TX 75024
Party NameNovast Laboratories, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressPlano, TX 75024

Trademark Events

Event DateEvent Description
Monday, November 13, 2023NEW APPLICATION ENTERED
Monday, December 11, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, February 6, 2024ASSIGNED TO EXAMINER
Monday, February 12, 2024NON-FINAL ACTION WRITTEN
Monday, February 12, 2024NON-FINAL ACTION E-MAILED
Monday, February 12, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, April 29, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, April 29, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, April 30, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, April 30, 2024FINAL REFUSAL WRITTEN
Tuesday, April 30, 2024FINAL REFUSAL E-MAILED
Tuesday, April 30, 2024NOTIFICATION OF FINAL REFUSAL EMAILED
Tuesday, April 30, 2024TEAS REQUEST FOR RECONSIDERATION RECEIVED
Tuesday, April 30, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, April 30, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, May 1, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 15, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, June 4, 2024PUBLISHED FOR OPPOSITION
Tuesday, June 4, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 30, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, December 31, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, December 31, 2024SOU EXTENSION 1 FILED
Tuesday, December 31, 2024SOU EXTENSION 1 GRANTED
Monday, March 3, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 17, 2025SOU TEAS EXTENSION RECEIVED
Thursday, July 17, 2025SOU EXTENSION 2 FILED
Thursday, July 17, 2025SOU EXTENSION 2 GRANTED
Friday, July 18, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, January 23, 2026SOU TEAS EXTENSION RECEIVED
Friday, January 23, 2026SOU EXTENSION 3 FILED
Friday, January 23, 2026SOU EXTENSION 3 GRANTED
Saturday, January 24, 2026NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Related Keywords

maylandi preparations replacement therapy hormone menopausal treatment pharmaceutical symptoms